Urogenital Neoplasms  >>  Torisel (temsirolimus)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Torisel (temsirolimus) / Pfizer
NCT00563147: A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma

Checkmark Data
Nov 2011 - Nov 2011: Data
Checkmark Data
Nov 2011 - Nov 2011: Data
Completed
1b
28
US
tivozanib (AV-951) plus temsirolimus, Torisel (temsirolimus)
AVEO Pharmaceuticals, Inc.
Renal Cell Carcinoma
11/10
02/11
NCT00523432: A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies

Completed
1
15
US
Topotecan, CCI-779 (temsirolimus)
University of Chicago, Wyeth is now a wholly owned subsidiary of Pfizer
Genital Neoplasms, Female
09/09
12/10
NCT01155258: Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Completed
1
19
US
temsirolimus, CCI-779, cell cycle inhibitor 779, rapamycin analog CCI-779, Torisel, vinorelbine ditartrate, Biovelbin, Eunades, navelbine ditartrate, NVB, vinorelbine tartrate, VNB
University of Southern California, Wyeth is now a wholly owned subsidiary of Pfizer
Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma, Male Breast Cancer, Malignant Paraganglioma, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Pheochromocytoma, Pancreatic Polypeptide Tumor, Recurrent Breast Cancer, Recurrent Cervical Cancer, Recurrent Endometrial Carcinoma, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Recurrent Neuroendocrine Carcinoma of the Skin, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pheochromocytoma, Recurrent Prostate Cancer, Recurrent Renal Cell Cancer, Recurrent Small Cell Lung Cancer, Recurrent Uterine Sarcoma, Regional Gastrointestinal Carcinoid Tumor, Regional Pheochromocytoma, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage III Neuroendocrine Carcinoma of the Skin, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage III Prostate Cancer, Stage III Renal Cell Cancer, Stage III Uterine Sarcoma, Stage IIIA Breast Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Endometrial Carcinoma, Stage IV Neuroendocrine Carcinoma of the Skin, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Prostate Cancer, Stage IV Renal Cell Cancer, Stage IV Uterine Sarcoma, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Thyroid Gland Medullary Carcinoma
01/13
05/14
NCT01122615: Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)

Checkmark ASCO-GU 2014
Jan 2014 - Jan 2014: ASCO-GU 2014
Completed
1
23
US
Sunitinib, Sunitinib Malate, Sutent, Temsirolimus, CCI-779, Torisel
M.D. Anderson Cancer Center, Pfizer
Renal Cell Cancer, Kidney Cancer
07/14
07/14

Download Options